Thursday, Nov 18, 2004

Genentech Announces November 18 Webcast Discussion of Tarceva FDA Approval

South San Francisco, Calif. -- November 18, 2004 --

Genentech, Inc. (NYSE: DNA) will be offering a live webcast of a discussion by Genentech management regarding the approval by the United States Food and Drug Administration of Tarceva™ (erlotinib).

The live webcast will begin on November 18, 2004 at 6:30pm Pacific Time and may be accessed on Genentech's website at http://www.gene.com. An archive of this webcast will be available until 5:00pm Pacific Time on November 25, 2004. A telephone audio replay of the webcast will be available beginning at 9:30pm Pacific Time on November 18, 2004 through 5:00pm Pacific Time on November 25, 2004. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is: 2052243.

About Genentech
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.